Initial combining lamivudine and adefovir dipivoxil and lamivudine/entecavir monotherapy in hepatitis B e antigen-positive chronic hepatitis B with high viral load

摘要

Background: Long-term treatment with nucleos(t)ide analogues (NUCs) is highly effective but HBeAg seroconversion and HBsAg loss are very rare and unsatisfied event in CHB patients with high viral load and, the resistance mutation and high relapse rates block benefit from antiviral treatment as well. The aim of the present study is to evaluate the efficacy and safety of a new therapeutic strategy initial combining Lamivudine(LAM) and Adefovir dipivoxil(ADV) in patients with HBeAg-positive chronic hepatitis B(CHB).